[go: up one dir, main page]

PE20170305A1 - SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN - Google Patents

SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Info

Publication number
PE20170305A1
PE20170305A1 PE2016002763A PE2016002763A PE20170305A1 PE 20170305 A1 PE20170305 A1 PE 20170305A1 PE 2016002763 A PE2016002763 A PE 2016002763A PE 2016002763 A PE2016002763 A PE 2016002763A PE 20170305 A1 PE20170305 A1 PE 20170305A1
Authority
PE
Peru
Prior art keywords
paracetamol
celecoxib
treatment
inflammatory pain
synergistic combination
Prior art date
Application number
PE2016002763A
Other languages
Spanish (es)
Inventor
Medellin Jorge Fernando Cantu
Original Assignee
More Pharma Corp S De R L De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corp S De R L De C V filed Critical More Pharma Corp S De R L De C V
Publication of PE20170305A1 publication Critical patent/PE20170305A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a una combinacion farmaceutica sinergistica util para el tratamiento de dolor inflamatorio, caracterizada porque comprende entre 375 mg y 500 mg de paracetamol y entre 50 mg y 75 mg de celecoxib. Tambien se refiere a una composicion farmaceutica que lo comprendeIt refers to a synergistic pharmaceutical combination useful for the treatment of inflammatory pain, characterized in that it comprises between 375 mg and 500 mg of paracetamol and between 50 mg and 75 mg of celecoxib. It also refers to a pharmaceutical composition comprising it

PE2016002763A 2013-07-11 2014-07-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN PE20170305A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/055710 WO2015004505A1 (en) 2013-07-11 2013-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain

Publications (1)

Publication Number Publication Date
PE20170305A1 true PE20170305A1 (en) 2017-04-21

Family

ID=52279400

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016000043A PE20160239A1 (en) 2013-07-11 2014-07-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN
PE2016002763A PE20170305A1 (en) 2013-07-11 2014-07-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016000043A PE20160239A1 (en) 2013-07-11 2014-07-11 SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN

Country Status (8)

Country Link
CL (1) CL2015003211A1 (en)
CR (1) CR20160021A (en)
CU (1) CU24440B1 (en)
DO (1) DOP2016000008A (en)
EC (1) ECSP16005679A (en)
MX (1) MX366118B (en)
PE (2) PE20160239A1 (en)
WO (2) WO2015004505A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package
PE20251234A1 (en) * 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V CELECOXIB-ACETAMINOPHEN COMBINATION WITH ENHANCED STABILITY AND PROCEDURE FOR ITS PREPARATION
PE20251233A1 (en) 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V MULTIACTIVE TABLET FOR THE TREATMENT AND CONTROL OF SEVERE CHRONIC PAIN AND PREPARATION METHOD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003208485B2 (en) * 2002-02-19 2009-05-28 Adcock Ingram Limited Pharmaceutical combinations of COX-2 inhibitors and opiates
GB0423103D0 (en) * 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents

Also Published As

Publication number Publication date
MX366118B (en) 2019-06-27
CU20160002A7 (en) 2016-06-29
MX2015013911A (en) 2015-12-08
CU24440B1 (en) 2019-09-04
PE20160239A1 (en) 2016-05-13
CL2015003211A1 (en) 2016-04-29
WO2015004505A1 (en) 2015-01-15
WO2015004634A3 (en) 2015-04-09
WO2015004634A2 (en) 2015-01-15
DOP2016000008A (en) 2016-03-15
CR20160021A (en) 2016-04-08
ECSP16005679A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
MX2021003230A (en) PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM.
CL2018000222A1 (en) New combination for use in cancer treatment
CL2016001231A1 (en) Autotaxin Inhibitor Compounds
MX378273B (en) ACTIVE COMPOUNDS TOWARDS BROMODOMAINS.
MY196173A (en) Cot Modulators And Methods Of Use Thereof
CL2015002658A1 (en) Derivatives of 2,3-disubstitute 1- acyl-4-amino-1,2,3,4-tetrahydroquiniline and its use as bromodomain inhibitors
CL2016001547A1 (en) Compositions for oral care
MX2015009104A (en) Solid solution compositions and use in cardiovascular disease.
CL2015002677A1 (en) Compositions comprising selenium and their use for the treatment and prevention of diseases or conditions associated with mitochondrial dysfunction.
MX2016007111A (en) Inhibitors of bruton's tyrosine kinase.
CR20110596A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
GT201700138A (en) PIRAZOLPIRIDINAMINAS
WO2014153009A3 (en) Thiosaccharide mucolytic agents
MX2018012285A (en) TREATMENT METHODS FOR COLESTIC AND FIBROTIC DISEASES.
CL2016001350A1 (en) Proto-action ketoprofen compositions.
PE20170305A1 (en) SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB FOR THE TREATMENT OF INFLAMMATORY PAIN
CL2015003460A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for the treatment of an ophthalmic disease
CL2015002188A1 (en) Topical eye analgesic agents
CL2016002655A1 (en) Pharmaceutical composition for the treatment of pain-related allopathies, using as active agent ketorolac tromethamine and tramadol hydrochloride
AR106415A1 (en) PHARMACEUTICAL COMPOSITION FOR PAIN TREATMENT
CL2016001054A1 (en) Compounds for the treatment of diabetes and complications of diseases derived from it
MX2017008879A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MICOSIS.
CO7170180A2 (en) Injectable pharmaceutical composition of dexketoprofen and tramadol